The intended audience for this educational initiative is primary care clinicians who are responsible for identifying patients that would benefit from LDL-C lowering and for initiating and intensifying primary and secondary prevention.
The goal of this program is to improve the knowledge and competence of primary care clinicians who manage patients with elevated LDL-C levels to reduce ASCVD risk
Upon completion of this activity, participants should be able to:
Assess the efficacy, safety, and mechanism of action of nonstatin agents approved to manage LDL-C levels
Devise individualized evidence-based primary prevention plans for patients with elevated LDL-C levels
Develop personalized strategies for secondary prevention for patients with elevated LDL-C levels using evidence-based guidelines
Escalate treatment of elevated LDL-C levels by incorporating approved nonstatin agents when statins alone do not achieve 2018 blood cholesterol guideline goals
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Ty Gluckman, MD, MHA, FACC, FAHA, FASPC
Medical Director, Center for Cardiovascular Analytics, Research and Data Science (CARDS) Providence Heart Institute
Providence St. Joseph Health
Ty Gluckman, MD, MHA, FACC, FAHA, FASPC, has no relevant financial relationships to disclose.
Viet Le, DMSc, PA-C, FACC, FAHA
Associate Professor of Research
Division of Cardiovascular Research
Intermountain Heart Institute
Cardiovascular Prevention Physician Associate
Department of Cardiology
Salt Lake City, Utah
Viet Le, MPAS, PA-C, FACC, FAHA: researcher (paid to institution): Amarin, Lilly, Milestones, Novartis.
Erin Michos, MD, MHS
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Associate Professor of Medicine & Epidemiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co-Editor in Chief, the American Journal of Preventive Cardiology
Erin Michos, MD, MHS: consultant/advisor/speaker: Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, Pfizer.
Margo B. Minissian, PhD, ACNP, FAHA, FNLA
Executive Director, Geri and Richard Brawerman Nursing Institute
Simms/ Mann Family Foundation Endowed Chair in Nurse Education,
Innovation and Research
Assistant Professor, Cardiology
Los Angeles, CA
The planners and content peer reviewers from USF Health, Rockpointe, and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
The content for this activity was peer reviewed by Karim Hanna, MD.
Dr. Hanna does not have any financial interests/relationships or affiliations in relation to this activity.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 14, 2023, through April 13, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
Physician Continuing Medical Education
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23036015. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Physician Assistant/Physician Associate Continuing Medical Education
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 4/4/2023 to 9/4/2024. AAPA reference number: CME-209116.
AAFP Credit Designation
The AAFP has reviewed Managing Elevated LDL-C Levels to Reduce ASCVD Risk: Primary and Secondary Prevention, and deemed it acceptable for AAFP credit. Term of approval is from 04/04/2023 to 08/01/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM’s) Maintenance of Certification (MOC) program. It is USF Health’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Diplomat’s MOC Points. No ABIM MOC Points certificates will be provided. Diplomats with questions regarding their Points, should contact USF Health at firstname.lastname@example.org.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).